nivolumab
bms
['solid tumor', 'nivolumab', 'nivo']
today, prof. kevin harrington (icr/ ) will present on a trial of rp2, a first-in-class, enhanced potency oncolytic hsv expressing an anti-ctla-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors in the #asco22 poster session. 
The Institute of Cancer Research is making the discoveries that defeat cancer. We're the UK's top academic research centre, a postgrad college, and a charity.